TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06644183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roginolisib
Description: Phosphoinositide 3-kinase delta inhibitor, 40 mg capsule, taken orally per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roginolisib
Description: Phosphoinositide 3-kinase delta inhibitor, 40 mg capsule, taken orally per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roginolisib
Description: Phosphoinositide 3-kinase delta inhibitor, 40 mg capsule, taken orally per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: B-cell lymphoma 2 inhibitor, 10, 50, and 100mg tablets, taken orally per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: B-cell lymphoma 2 inhibitor, 10, 50, and 100mg tablets, taken orally per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: B-cell lymphoma 2 inhibitor, 10, 50, and 100mg tablets, taken orally per standard of care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venetoclax
Description: B-cell lymphoma 2 inhibitor, 10, 50, and 100mg tablets, taken orally per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Chimeric anti-CD 20 monoclonal antibody, single-use 10 and 50mL vials, via intravenous (into the vein) infusion per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Chimeric anti-CD 20 monoclonal antibody, single-use 10 and 50mL vials, via intravenous (into the vein) infusion per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Chimeric anti-CD 20 monoclonal antibody, single-use 10 and 50mL vials, via intravenous (into the vein) infusion per standard of care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Chimeric anti-CD 20 monoclonal antibody, single-use 10 and 50mL vials, via intravenous (into the vein) infusion per standard of care.
Study: NCT05545397

Intervention type: DRUG
Intervention: Propofol
Description: And pump propofol at a rate of 600ml/h. The degree of sedation was assessed by the MOAA/S scale until the depth sadation of the patient during the monitor of EEG

Intervention type: DEVICE
Intervention: EEG montior
Description: And pump propofol at a rate of 600ml/h. The degree of sedation was assessed by the MOAA/S scale until the depth sadation of the patient during the monitor of EEG
Study: NCT04811079

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 419 nm Spectacle Filter
Description: TEST

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 419 nm Spectacle Filter
Description: TEST

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 419 nm Spectacle Filter
Description: TEST

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 419 nm Spectacle Filter
Description: TEST

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 419 nm Spectacle Filter
Description: TEST

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 437 nm Spectacle Filter
Description: TEST

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 437 nm Spectacle Filter
Description: TEST

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 437 nm Spectacle Filter
Description: TEST

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 437 nm Spectacle Filter
Description: TEST

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 437 nm Spectacle Filter
Description: TEST

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 437 nm Spectacle Filter
Description: TEST
Study: NCT03984565

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sublingual product formulated in palm oil with supplemental terpenes to match CBD product.
Study: NCT04811079

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 437 nm Spectacle Filter
Description: TEST

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 437 nm Spectacle Filter
Description: TEST

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 437 nm Spectacle Filter
Description: TEST

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 437 nm Spectacle Filter
Description: TEST

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 456 nm Spectacle Filter
Description: TEST

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 456 nm Spectacle Filter
Description: TEST

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 456 nm Spectacle Filter
Description: TEST

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 456 nm Spectacle Filter
Description: TEST

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 456 nm Spectacle Filter
Description: TEST

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 456 nm Spectacle Filter
Description: TEST

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 456 nm Spectacle Filter
Description: TEST

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 456 nm Spectacle Filter
Description: TEST

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 456 nm Spectacle Filter
Description: TEST

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 456 nm Spectacle Filter
Description: TEST

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 476 nm Spectacle Filter
Description: TEST

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 476 nm Spectacle Filter
Description: TEST

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 476 nm Spectacle Filter
Description: TEST

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 476 nm Spectacle Filter
Description: TEST
Study: NCT05129631

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEARTPrep
Description: HEARTPrep is a virtually-delivered psychosocial intervention for mothers expecting a baby with CHD.
Study: NCT04811079

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 476 nm Spectacle Filter
Description: TEST

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 476 nm Spectacle Filter
Description: TEST

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 476 nm Spectacle Filter
Description: TEST

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 476 nm Spectacle Filter
Description: TEST

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 476 nm Spectacle Filter
Description: TEST

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 476 nm Spectacle Filter
Description: TEST

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 373 nm Spectacle Filter
Description: CONTROL
Study: NCT04718090

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PENG Block
Description: Pericapsular nerve group block in shoulder surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PENG Block
Description: Pericapsular nerve group block in shoulder surgery.
Study: NCT06067477

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D Supplement
Description: Vitamin D Supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D Supplement
Description: Vitamin D Supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D Supplement
Description: Vitamin D Supplement
Study: NCT05738980

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous RAK cells
Description: Autologous RAK cells were treated by intravenous reinfusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous RAK cells
Description: Autologous RAK cells were treated by intravenous reinfusion
Study: NCT05727774

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Biking in hot water condition
Description: Training protocol includes 10 water biking sessions in hot water temperature (35°C) for this group

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Water Biking in neutral water condition
Description: Training protocol includes 10 water biking sessions in neutral water temperature (25°C) for this group
Study: NCT06152081

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LumiCare rinse
Description: The teeth being assessed will be cleaned of any debris ,plaque and calculus. The areas being assessed will be air dried. A dry field will be maintained using cotton rolls and a saliva ejector. Lumicare rinse will be applied onto the test areas for 30 seconds and the excess removed using a saliva ejector. The sites will then be rinsed with plain water for 10 seconds and excess will be removed using high volume suction. A blue curing light will then be held 1-2 inches from the test surfaces while the examiner assesses the surfaces for the presence or absence of fluorescent illumination.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QLF Inspektor Pro Imaging
Description: The teeth being assessed will be cleaned of any debris ,plaque and calculus. The areas being assessed will be air dried. A dry field will be maintained using cotton rolls and a saliva ejector. The QLF device will be positioned over the tooth surface to be tested and an image will be taken. The images will be stored automatically and assessed by the examiners for the presence of green fluorescence using the QA2 program (Version 1.25, Inspektor Research systems BV, Amsterdam, The Netherlands) . The trend in green fluorescence will also be calculated using this software algorithm.
Study: NCT06455514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: 4 g of magnesium sulfate intravenously within 2 hours of Return of Spontaneous Circulation (ROSC), followed by a continuous drip (16 g) over 24 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Control subjects will receive an equivalent volume of normal saline intravenously.
Study: NCT06395246

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Continuous calorie restriction
Description: Individualized continuous calorie restriction diet based on healthy Mediterranean diet recommendations aiming to achieve at least a 5% weight loss at the end of the intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eTRE
Description: early (morning) time-restricted eating pluss individualized continuous calorie restriction diet based on healthy Mediterranean diet recommendations aiming to achieve at least a 5% weight loss at the end of the intervention
Study: NCT06213649

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Polyhexamethylene biguanide (PHMB)
Description: PHMB is a cationic antiseptic agent used for topical treatment of acanthamoeba keratitis (AK). Both treatment groups will take PHMB at least 4 times daily while on the allocated study drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyhexamethylene biguanide (PHMB)
Description: PHMB is a cationic antiseptic agent used for topical treatment of acanthamoeba keratitis (AK). Both treatment groups will take PHMB at least 4 times daily while on the allocated study drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical corticosteroid
Description: Dexamethasone sodium phosphate, 0.1% ophthalmic solution will be administered 4 times daily for 4 weeks, then 2 times daily for 2 weeks, then 1 time daily for 2 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Topical placebo
Description: An artificial tear ophthalmic solution will be administered 4 times daily for 4 weeks, then 2 times daily for 2 weeks, then 1 time daily for 2 weeks.
Study: NCT06440343

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrates
Description: 60g of maltodextrin + fructose, 2:1 ratio

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05335369

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UR-GOAL
Description: UR-GOAL helps conducts assessments of fitness, elicits patient values via Best-Worst Scaling, and elicits preferences for prognostic information and assesses prognostic awareness. The tool also includes an AML educational video.
Study: NCT05387408

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Best Practice Health and Employment Opioid-related Policies
Description: The intervention will include information to promote policies and programs to prevent opioid abuse and aid recovery such as drug testing for opioids, health and employee assistance programs, job accommodations, and education to deliver training to prevent opioid use, and prevent stigma.
Study: NCT05432557

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: external oblique intercostal plain block (EOIP)
Description: A high-frequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation at the sixth intercostal space in the anterior midaxillary line. A 21G 10 cm needle will be inserted using an in plane approach. The tip of the needle will be placed into the fascial plane on the deep aspect of the external oblique muscle. A volume of 20 mL of LA mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine 2% and 5 mL of normal saline to make a mixture totaling 20 ml.) will be injected.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: subcostal transversus abdominis plane block (SCTAP)
Description: The US probe will be placed immediately below the costal margin on oblique plane toward the lateral close to midline to identify the rectus abdominis muscle. The transversus abdominis muscle will be identified lying posterior to the rectus muscle. An 8cm 22-gauge block needle will be inserted using an in- plane approach. transversus abdominis plane will be accessed by placing the needle adjacent to costal margin but medial to linea semilunaris. The needle will be advanced slowly in-plane to promote hydrodissection along the oblique subcostal line. A volume of 20 mL of LA mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine 2% and 5 mL of normal saline to make a mixture totaling 20 ml.) will be injected.
Study: NCT04015557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Adult patients with homocystinuria due to cystathionine beta synthase (CBS) deficiency and controls will receive a single dose of Acetaminophen (1.5g) orally. Blood will be drawn at time 0, 2, 4, 6 and 8 hours after the acetaminophen dose to measure liver enzymes and markers of oxidative stress.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Adult patients with homocystinuria due to cystathionine beta synthase (CBS) deficiency and controls will receive a single dose of Acetaminophen (1.5g) orally. Blood will be drawn at time 0, 2, 4, 6 and 8 hours after the acetaminophen dose to measure liver enzymes and markers of oxidative stress.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: Patients with homocystinuria due to cystathionine beta synthase (CBS) deficiency and controls will receive again a normal dose of acetaminophen (1.5g) orally and one hour later oral N-acetylcysteine (70 mg per kilogram of body weight). Blood will be drawn at time 0, 2, 4, 6 and 8 hours after the acetaminophen dose to measure liver enzymes and markers of oxidative stress.
Study: NCT06605703

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WW Clinic
Description: Telehealth platform that specializes in medical weight management and integrates the behavioral and lifestyle support from WW.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WW Clinic
Description: Telehealth platform that specializes in medical weight management and integrates the behavioral and lifestyle support from WW.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WW Clinic
Description: Telehealth platform that specializes in medical weight management and integrates the behavioral and lifestyle support from WW.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion-Naltrexone
Description: Bupropion-Naltrexone
Study: NCT04923971

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Purdue Pegboard
Description: Participants will assemble the pegboard with their left, right, and both hands in each environmental condition.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Purdue Pegboard
Description: Participants will assemble the pegboard with their left, right, and both hands in each environmental condition.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Purdue Pegboard
Description: Participants will assemble the pegboard with their left, right, and both hands in each environmental condition.
Study: NCT05755789

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loading bolus of cefoxitin
Description: Cefoxitin \[2g\] before incision

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loading bolus of cefoxitin
Description: Cefoxitin \[2g\] before incision

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent cefoxitin
Description: Additional bolus of cefoxitin \[1g\] every 2 hours until the end of surgical closure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous infusion of placebo
Description: Continuous infusion of placebo from the end of the loading bolus until the end of surgical closure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous infusion of cefoxitin
Description: Continuous infusion of cefoxitin \[0.5g/h\] from the end of the loading bolus until the end of surgical closure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intermittent placebo
Description: Additional bolus of placebo every 2 hours until the end of surgical closure
Study: NCT04850950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide fumarate 25mg Oral Tablet
Description: Tenofovir alafenamide fumarate initiated from the late pregnancy to the delivery date or postpartum month 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide fumarate 25mg Oral Tablet
Description: Tenofovir alafenamide fumarate initiated from the late pregnancy to the delivery date or postpartum month 1.
Study: NCT06375850

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sesame oil
Description: A peripheral venous catheter will be channeled to the patient admitted to the unit and who requires it. The indications included in the guide for channeling venous access of the Marqués de Valdecilla hospital will be followed.~Once the venous access has been channeled, it will be fixed with, leaving the puncture point visible for future monitoring.~The sesame oil chosen for the project is Sesame bio - 100% pure vegetable oil from the Naissance brand.~To perform the procedure, two drops of sesame oil will be applied daily by the nurse in charge of the patient during the morning shift in the area about 2 cm above the insertion point and coinciding with the course of the vein channeled for intravenous therapy. A small massage of the area of application will be performed, with an approximate extension of 3x3cm, until its absorption. It will be left to dry in the air.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: After cannulation of the vein following the same procedure as explained in the intervention arm, patients belonging to the control arm will be administered two drops of saline solution.
Study: NCT05975307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: The patients in this arm will receive 3 cycles of induction treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab.~Toripalimab: 240 mg on Day 1, every 3 weeks, totally 3 and 2 cycles in the induction and concurrent phases, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: The patients in this arm will receive 3 cycles of induction treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab.~Gemcitabine: 1 g/m2 on Days 1 and 8, repeated every 3 weeks, totally 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: The patients in this arm will receive 3 cycles of induction treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab.~Cisplatin: Used when creatinine clearance rate ≥ 40 ml/min, 37.5 mg/m2 on Days 1 and 2, repeated every 3 weeks, totally 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: The patients in this arm will receive 3 cycles of induction treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab.~Cisplatin: Used when creatinine clearance rate \< 40 ml/min, area under curve = 2 on Days 1 and 2, repeated every 3 weeks, totally 3 cycles.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy
Description: The patients in this arm will receive 3 cycles of induction treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab.~Radiotherapy: performed by using the technique of intensity-modulated radiation therapy, with a total dose of 65 and 45 Gy for the gross tumor and lymphatic drainage regions.
Study: NCT05087056

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MenABCWY vaccine
Description: Two doses of the MenABCWY vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, on a 0-, 24-month schedule in the ABCWY-24 Group, and a 0-, 48-month schedule in the ABCWY-48 Group.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MenABCWY vaccine
Description: Two doses of the MenABCWY vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, on a 0-, 24-month schedule in the ABCWY-24 Group, and a 0-, 48-month schedule in the ABCWY-48 Group.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose of Placebo (saline solution in pre-filled syringe), administered intramuscularly in the deltoid region of the non-dominant arm, at Day 1441 in the ABCWY-24 Group, and at Day 721 in the ABCWY-48 Group.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose of Placebo (saline solution in pre-filled syringe), administered intramuscularly in the deltoid region of the non-dominant arm, at Day 1441 in the ABCWY-24 Group, and at Day 721 in the ABCWY-48 Group.